Our Blog Melanoma360

Blog - Melanoma360

Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
Featured image for “Functional Nutrition for Cancer Survivors”
02/07/2023

Functional Nutrition for Cancer Survivors

In this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
Blog - Melanoma360
, 
Podcast
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “A Letter From Our Vice President | January 2023”
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Blog - Melanoma360
, 
Melanoma Research
Featured image for “The Grieving Brain: The Science of Love and Loss”
01/11/2023

The Grieving Brain: The Science of Love and Loss

Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at the…
Blog - Melanoma360
, 
Podcast
Featured image for “AIM at Melanoma Earns a Four-Star Rating From Charity Navigator”
12/23/2022

AIM at Melanoma Earns a Four-Star Rating From Charity Navigator

December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
Blog - Melanoma360
, 
Philanthropy
Featured image for “The Future of Melanoma Treatment: 2023 and Beyond”
12/19/2022

The Future of Melanoma Treatment: 2023 and Beyond

Melissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
Blog - Melanoma360
, 
Podcast
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Blog - Melanoma360
, 
Breaking News
, 
Melanoma Research
02/28/2023

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)–  The applications are based on results from the Phase 3 CheckMate -76K trial,…
Featured image for “U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/07/2023

Functional Nutrition for Cancer Survivors

In this episode, we welcome Dione Detraz, RD, integrative dietitian nutritionist and author of The Cancer Diet Cookbook: Comforting Recipes…
Featured image for “Functional Nutrition for Cancer Survivors”
Blog - Melanoma360
 | 
Podcast
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Featured image for “A Letter From Our Vice President | January 2023”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
Blog - Melanoma360
 | 
Melanoma Research
01/11/2023

The Grieving Brain: The Science of Love and Loss

Our guest Dr. Mary-Frances O’Connor is a renowned grief expert, author, neuroscientist, and an associate professor of psychology at the…
Featured image for “The Grieving Brain: The Science of Love and Loss”
Blog - Melanoma360
 | 
Podcast
12/23/2022

AIM at Melanoma Earns a Four-Star Rating From Charity Navigator

December 21, 2022 (Richmond, California) AIM at Melanoma is proud to announce that its strong financial health and ongoing accountability…
Featured image for “AIM at Melanoma Earns a Four-Star Rating From Charity Navigator”
Blog - Melanoma360
 | 
Philanthropy
12/19/2022

The Future of Melanoma Treatment: 2023 and Beyond

Melissa Wilson, PA-C, MPAS from UPMC Hillman Cancer Center, and Vernon Sondak, MD, Chair, Department of Cutaneous Oncology, Moffitt Cancer…
Featured image for “The Future of Melanoma Treatment: 2023 and Beyond”
Blog - Melanoma360
 | 
Podcast
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research

Recent Posts

Featured image for “Navigating the Journey Together – Conversations with Melanoma Caregivers”
Apr. 16, 2024

Navigating the Journey Together – Conversations with Melanoma Caregivers

Featured image for “May is Brain Tumor Awareness Month”
Apr. 12, 2024

May is Brain Tumor Awareness Month

Featured image for “President’s Letter | April 2024”
Apr. 11, 2024

President’s Letter | April 2024

Featured image for “Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk”
Apr. 11, 2024

Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk

Featured image for “Interview with Allison Betof Warner, MD, PhD: TIL Therapy”
Apr. 11, 2024

Interview with Allison Betof Warner, MD, PhD: TIL Therapy

Filter by Tag